1E Therapeutics

About

Funding history · 1 round · $120.0M total

Q&A

What is 1E Therapeutics' primary focus?

1E Therapeutics is a drug-development company creating RNA-targeting therapeutics based on a proprietary drug-design platform.

When was 1E Therapeutics founded?

1E Therapeutics was founded in July 2021.

What is the total amount of funding 1E Therapeutics has raised?

1E Therapeutics has raised a total of $120,000,000 USD.

Who was a lead investor in 1E Therapeutics' funding round in December 2021?

Marius Nacht was a lead investor in 1E Therapeutics' funding round in December 2021.

How many employees does 1E Therapeutics currently have?

1E Therapeutics has 11-50 employees.

In which country is 1E Therapeutics headquartered?

1E Therapeutics is headquartered in Israel.

What types of indications does 1E Therapeutics' drug development process address?

1E Therapeutics' process develops drugs that address chronic life-threatening indications, emerging and evolving pathogens, and has lead compounds for oncology, age-related diseases, immunology, anti-microbial resistance, viral infections, and orphan neurological disorders.

What is the current product stage of 1E Therapeutics?

1E Therapeutics is currently in the clinical trial stage.

Sectors & technology

Highlights

Tags